Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | Y30fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | CTNNB1 Y30fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 30 of 781, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known function domains (UniProt.org), Y30fs is predicted to lead to a loss of Ctnnb1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 inact mut CTNNB1 Y30fs |
Transcript | NM_001098210.2 |
gDNA | chr3:g.(41224599_41224600) |
cDNA | c.(88_87) |
Protein | p.Y30fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001904.4 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.(41224599_41224600) | c.(88_87) | p.Y30fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|